top of page

Selected Publications

Full List of Publications

Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy.

Clements AN, Casillas AL, Flores CE, Liou H, Toth RK, Chauhan SC, Sutterby K, Deshmukh SK, Wu S, Xiu J, Farrell A, Radovich M, Nabhan C, Heath EI, McKay RR, Subah N, Centouri S, Wheeler TJ, Cress AE, RogersGC, Wilson JE, Recio-Boiles A, and Warfel NA. Cancer Immunology Research. 2024 PMID 39982419​

​

SC liipd .webp

 PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. 
Torres-Ayuso P, Katerji M, Mehlich D, Lookingbill SA, Sabbasani VR, Liou H, Casillas AL, Chauhan SS, Serwa R, Rubin MR, Marusiak AA, Swenson RE, Warfel NA, Brognard J. Cell Chem Biol. 2023. PMID: 38016478. 

PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion.
Jensen CC, Clements AN, Liou H, Ball LE, Bethard JR, Langlais PR, Toth RK, Chauhan SS, Casillas AL, Daulat SR, Kraft AS, Cress AE, Miranti CK, Mouneimne G, Rogers GC, Warfel NA J Cell Biol. 2023 PubMed Central PMCID: PMC10103708. 

Hypoxia-inducible PIM kinase expression promotes resistance to antiangiogenic agents. A.L. Casillas, R.K. Toth, N. Singh, A.A. Desai, A.S. Kraft, and N.A. Warfel. Clinical Cancer Research 2018.

bottom of page